0001493152-25-024263 | 10-Q | XBRL Viewer

Cover - $ / shares	9 Months Ended
Cover - $ / shares	Sep. 30, 2025	Nov. 17, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2025
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--12-31
Entity File Number	001-41184
Entity Registrant Name	ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key	0001859007
Entity Tax Identification Number	86-2685744
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2200 N. Commerce Parkway
Entity Address, Address Line Two	Suite 208
Entity Address, City or Town	Weston
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33326
City Area Code	(754)
Local Phone Number	231-1688
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ZVSA
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,095,921
Entity Listing, Par Value Per Share	$ 0.0001

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Payroll accrual	$ 1,101,584	$ 1,039,338
Bonus accrual	1,107,813	536,500
Other accrued expenses	681,296	310,942
Accrued issuable equity	62,744
Registration delay liability	7,261	7,261
Total accrued expenses and other current liabilities	$ 2,960,698	$ 1,894,041

- Definition

Amount of liabilities classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 64
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481620/480-10-55-64

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Schedule of Warrant Activity (Details)

9 Months Ended

Sep. 30, 2025

USD ($)

$ / shares

Equity [Abstract]

Number of warrants, outstanding beginning balance | shares

1,747,093

Weighted average exercise price, beginning balance | $ / shares

$ 59.59

Number of warrants, Issued | shares

8,230,195

^[1]

Weighted average exercise price, Issued | $ / shares

$ 0.75

^[1]

Number of warrants, repriced - old | shares

(957,200)

^[2]

Weighted average exercise price, repriced - old | $ / shares

$ 2.06

^[2]

Number of warrants, repriced - new | shares

957,200

^[2]

Weighted average exercise price, repriced - new | $ / shares

$ 1.00

^[2]

Number of warrants, repriced - old four | shares

(957,200)

^[3]

Weighted average exercise price, repriced - old | $ / shares

$ 1.00

^[3]

Number of warrants, repriced - new | shares

957,200

^[3]

Weighted average exercise price, repriced - new | $ / shares

$ 0.67

^[3]

Number of warrants, repriced - old four | shares

(2,105,265)

^[4]

Weighted average exercise price, repriced - old | $ / shares

$ 1.00

^[4]

Number of warrants, repriced - new | shares

2,105,265

^[4]

Weighted average exercise price, repriced - new | $ / shares

$ 0.67

^[4]

Number of warrants, forfeited | shares

(3,050)

Weighted average exercise price, forfeited | $ / shares

$ 12.50

Number of warrants, exercised | shares

(3,062,465)

^[1]

Weighted average exercise price, exercised | $ / shares

$ 0.67

^[1]

Number of warrants, outstanding ending balance | shares

6,911,773

Weighted average exercise price, ending balance | $ / shares

$ 15.34

Weighted average remaining life in years, outstanding

4 years 8 months 23 days

Aggregate intrinsic value, ending balance | $

Number of warrants, exercisable ending balance | shares

6,911,573

Weighted average exercise price, Exercisable | $ / shares

$ 15.29

Weighted average remaining life in years, exercisable

4 years 8 months 23 days

Aggregate intrinsic value, exercisable | $

[1]	Warrants issued and exercised exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.
[2]	Warrants represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.
[3]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 957,200 shares of common stock from $1.00 to $0.67 per share.
[4]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 2,105,265 shares of common stock from $1.00 to $0.67 per share.

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares

9 Months Ended

Sep. 30, 2025

Sep. 30, 2024

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

7,301,336

940,371

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

^[1]

6,911,773

928,593

Share-Based Payment Arrangement, Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

387,424

9,639

Series A Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

Series B Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

2,067

[1]	As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2025

Accounting Policies [Abstract]

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	As of September 30,
	2025		2024
Warrants ^[1]		6,911,773		928,593
Options		387,424		9,639
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		7,301,336		940,371

[1]

As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.

Segment Reporting

The Company has one operating and reporting segment (clinical stage biopharmaceutical), namely, the development of drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker (“CODM”), who is the Company’s chief executive officer, utilizes the Company’s financial information on an aggregate, consolidated basis for purposes of making operating decisions, allocating resources and assessing financial performance, as well as for making strategic operations decisions and managing the organization. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the condensed consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total assets. The Company has not yet generated any revenue from product sales.

Vendor Concentration

As of September 30, 2025 and December 31, 2024, accounts payable to one vendor accounted for 56% and 56%, respectively, related to research and development. The Company relies on this vendor to perform critical research and development.

Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the requirement to disclose additional specified categories in the rate reconciliation in both percentage and dollar amounts. The standard, which is effective for the Company’s 2025 annual period, will be applied.

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220 – 04). This update requires an entity to disclose more detailed information regarding expenses for the entity. The amendments require that at each interim and the annual reporting period, the entity must disclose amounts related to purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Including the amounts, the entity is required to disclose and qualitative description of the amounts remaining in relevant expense captions, and to disclose the total amount of selling expenses and the definition of selling expenses. The amendments in this update should be applied prospectively to financial statements issued for reporting periods, and retrospectively to any prior periods presented in the financials. Although early adoption is permitted, the new guidance becomes effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows.

- Definition

Disclosure of accounting policy for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 36
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-36

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

+ Details

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

+ Details

Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share (Details) (Parenthetical) - shares	Sep. 30, 2025	Sep. 30, 2024
Inflamacore, LlC License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase common shares	342	342

Stockholders’ (Deficit) Equity (Details Narrative) - USD ($)									3 Months Ended			9 Months Ended
	Aug. 01, 2025	Jul. 11, 2025	Jul. 08, 2025	Jun. 24, 2025	May 01, 2025	Mar. 20, 2025	Mar. 07, 2025	Feb. 02, 2025	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	May 13, 2025	Apr. 11, 2025	Nov. 05, 2024	Nov. 04, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds warrants				$ 10,000,000.0									$ 2,672,500
Fair value				265,957
Additional issuance costs				$ 74,000
Stock based compensation expense									$ 73,988		$ 160,665	205,478	544,902
Unrecognized stock-based compensation expense									$ 317,710			$ 317,710
Weighted average period		3 years										1 year 10 months 24 days
Exercise price			$ 1.00
Gross proceeds												$ 1,999,791
Warrant term									5 years			5 years
Other costs									$ 175,221	$ 282,849	427,054
Inducement Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price			$ 0.67
Other fees			$ 41,851
Number of shares of common stock issued pursuant to the holder's exercise of existing warrants rate			$ 2
March 2025 PreFunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price									$ 0.0001			$ 0.0001
December 2023 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds warrants		$ 201,296
Private Placement [Member] \| March 2025 PreFunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price							$ 0.0001
Warrant purchase							2,105,265
Transaction costs												$ 282,849
Placement fees												199,863
Other fees												56,844
Other costs												26,142
Private Placement [Member] \| March 2025 Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant purchase							2,105,265
Private Placement [Member] \| March 2025 Common Warrants And Prefunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price							$ 0.9499									$ 1.00	$ 2.06
Warrant purchase																957,200
Gross proceeds							$ 2,000,000.0
Transaction costs							$ 53,890
Research and Development Expense [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock based compensation expense									$ 17,362		15,447	48,256	46,342
General and Administrative Expense [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock based compensation expense									$ 56,626		$ 145,218	$ 157,222	$ 498,560
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant modification costs			$ 1,762,756
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants		377,964		426,829
Exercise price		$ 0.59
Series A2 Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant purchase			957,200
Series A3 Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant purchase			2,105,265
Series A4 Common Stock [Member] \| Inducement Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price			$ 0.67
Warrant purchase			6,124,930
Transaction costs			$ 175,221
Warrant term			5 years
Proceeds from issuance of common stock			$ 2,051,852
Cash fee paid			$ 133,370
Marketing Agreements [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued period of shares, common stock	160,000				100,000	100,000		60,000
Prepaid expense	$ 29,600				$ 51,800	$ 70,100		$ 81,600
Number of common stock for future issuance	160,000													100,000	100,000
Vendor market value	$ 29,600													$ 51,800	$ 77,000
Equity Purchase Agreement [Member] \| ELOC Shares [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds warrants				$ 10,000,000.0

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2025

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of September 30, 2025 and December 31, 2024:

	September 30,		December 31,
	2025		2024

Payroll accrual	$	1,101,584	$	1,039,338
Bonus accrual		1,107,813		536,500
Other accrued expenses		681,296		310,942
Accrued issuable equity		62,744		-
Registration delay liability		7,261		7,261
Total accrued expenses and other current liabilities	$	2,960,698	$	1,894,041

Summary of Significant Accounting Policies (Details Narrative) - Segment	9 Months Ended	12 Months Ended
	Sep. 30, 2025	Dec. 31, 2024
Product Information [Line Items]
Number of operating segment	1
Number of reportable segment	1
Accounts Payable [Member] \| Customer Concentration Risk [Member] \| One Vendor [Member]
Product Information [Line Items]
Concentration risk percentage	56.00%	56.00%

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details

Income Taxes

9 Months Ended

Sep. 30, 2025

Income Tax Disclosure [Abstract]

Income Taxes

Note 6 – Income Taxes

The Company’s effective tax rate was 3.39% and (0.12%) for the nine months ended September 30, 2025 and 2024, respectively. The increase in the quarterly rate is primarily the result of adjustments in its valuation allowance. During the nine months ended September 30, 2025, the Company recorded an impairment on the IPR&D asset which resulted in a decrease to the related deferred tax liability balance.

Tax Law Change

On July 4th, 2025, the President signed into law significant federal tax legislation, H.R.1 (the “Tax Reform Act of 2025”). The legislation includes numerous changes to U.S. corporate income tax law, including but not limited to: permanent 100% bonus depreciation for qualified property, immediate expensing of domestic research and experimental expenditures, modifications to the limitation on business interest expense, increased Section 179 expensing limits, changes to the international tax regime, and expanded limitations on the deductibility of executive compensation under IRC Section 162(m). Most provisions are effective for tax years beginning after December 31, 2024, with certain transition rules and exceptions.

The Company has evaluating the impact of the Tax Reform Act of 2025 on its condensed consolidated financial statements. There was no material impact given the Company’s tax loss profile and valuation allowance position.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Schedule of Stock Options Granted (Details) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2025
Equity [Abstract]
Fair value of common stock on date of grant	$ 0.59	$ 0.59
Risk free interest rate	4.09%	4.09%
Expected term (years)	6 years	6 years
Expected volatility	130.00%	130.00%
Expected dividends	0.00%	0.00%

In-Process Research and Development

9 Months Ended

Sep. 30, 2025

Research and Development [Abstract]

In-Process Research and Development

Note 4 – In-Process Research and Development

In December of 2022, in connection with a business combination, the Company recorded an indefinite-lived intangible asset related to in-process research and development (“IPR&D”). ASC 350 requires that intangible assets with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. As of September 30, 2025, management determined that it was more likely than not that the Company’s single reporting unit’s fair value was below its carrying amount, due to a significant and sustained decline in the Company’s market capitalization through September 30, 2025, therefore an impairment test was performed on the Company’s IPR&D intangible asset.

Current limitations on accessing significant capital in what is currently a risk averse environment for biotech (as evidenced by decreased investor appetite for risk, market volatility, regulatory uncertainty from a changing Food and Drug Administration and a challenging economic environment), has resulted in a sustained decline in the Company’s market capitalization, and the Company’s ability to further finance the development of its drug candidates to the next milestone could be adversely impacted. Accordingly, the Company determined that the carrying value of its IPR&D intangible asset may not be recoverable and it was fully impaired. Therefore, the Company recorded an $18.6 million impairment charge, reflected within operating expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2025.

Insider Trading Arrangements	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2025
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2025	Dec. 31, 2024
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	8,095,928	2,508,198
Common stock, shares outstanding	8,095,921	2,508,191
Treasury stock, shares	7	7
Series A Preferred Stock [Member]
Preferred stock, shares authorized	8,635	8,635
Preferred stock, shares issued	50	50
Preferred stock, shares outstanding	50	50
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,062	5,062
Preferred stock, shares issued	5,062	5,062
Preferred stock, shares outstanding	5,062	5,062

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	As of September 30,
	2025		2024
Warrants ^[1]		6,911,773		928,593
Options		387,424		9,639
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		7,301,336		940,371

[1]

Income Taxes (Details Narrative)		9 Months Ended
Income Taxes (Details Narrative)	Jul. 04, 2025	Sep. 30, 2025	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Effective income tax percentage		3.39%	0.12%
Depreciation bonus percentage	100.00%

Schedule of Information Related to Stock Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2025	Dec. 31, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants, outstanding	6,911,773	1,747,093
Options exercisable, Number of options	6,911,573
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants, outstanding	6,911,773
Warrant exercisable, weighted average remaining life in years	4 years 8 months 23 days
Options exercisable, Number of options	6,911,573
Exercise Price One [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 0.67
Number of warrants, outstanding	6,124,930
Warrant exercisable, weighted average remaining life in years	4 years 9 months 7 days
Options exercisable, Number of options	6,124,930
Exercise Price Two [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 2.06
Number of warrants, outstanding	679,800
Warrant exercisable, weighted average remaining life in years	4 years 8 months 8 days
Options exercisable, Number of options	679,800
Exercise Price Three [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 12.50
Number of warrants, outstanding	4,050
Warrant exercisable, weighted average remaining life in years	3 years 2 months 12 days
Options exercisable, Number of options	4,050
Exercise Price Four [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 47.50
Number of warrants, outstanding	20,347
Warrant exercisable, weighted average remaining life in years	3 years 5 months 12 days
Options exercisable, Number of options	20,347
Exercise Price Five [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 57.75
Number of warrants, outstanding	19,965
Warrant exercisable, weighted average remaining life in years	2 years 9 months 7 days
Options exercisable, Number of options	19,965
Exercise Price Six [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 350.00
Number of warrants, outstanding	27,551
Warrant exercisable, weighted average remaining life in years	2 years 6 months 25 days
Options exercisable, Number of options	27,551
Exercise Price Seven [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 700.00
Number of warrants, outstanding	13,944
Warrant exercisable, weighted average remaining life in years	2 years 2 months 12 days
Options exercisable, Number of options	13,944
Exercise Price Eight [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 1,760.50
Number of warrants, outstanding	200
Exercise Price Nine [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 2,415.00
Number of warrants, outstanding	3,651
Warrant exercisable, weighted average remaining life in years	2 years 2 months 12 days
Options exercisable, Number of options	3,651
Exercise Price Ten [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 4,025.00
Number of warrants, outstanding	17,335
Warrant exercisable, weighted average remaining life in years	2 years 2 months 12 days
Options exercisable, Number of options	17,335

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating Expenses:
Research and development	$ 365,053	$ 436,043	$ 1,033,865	$ 1,658,030
General and administrative	1,739,174	1,833,578	5,259,064	6,192,205
Impairment of in-process research and development	18,647,903		18,647,903
Total Operating Expenses	20,752,130	2,269,621	24,940,832	7,850,235
Loss From Operations	(20,752,130)	(2,269,621)	(24,940,832)	(7,850,235)
Other (Income) Expense:
Interest expense	131,350	131,635	380,946	131,794
Change in fair value of equity payable	(226,262)		(196,313)
Pre-Tax Net Loss	(20,657,218)	(2,401,256)	(25,125,465)	(7,982,029)
Income tax benefit (provision)	851,659		851,659	(9,707)
Net Loss	$ (19,805,559)	$ (2,401,256)	$ (24,273,806)	$ (7,991,736)
Net Loss Per Share
Basic	$ (2.56)	$ (2.43)	$ (4.63)	$ (9.79)
Diluted	$ (2.56)	$ (2.43)	$ (4.63)	$ (9.79)
Weighted Average Number of Common Shares Outstanding
Basic	7,740,678	988,378	5,237,544	816,293
Diluted	7,740,678	988,378	5,237,544	816,293

Stockholders’ (Deficit) Equity

9 Months Ended

Sep. 30, 2025

Equity [Abstract]

Stockholders’ (Deficit) Equity

Note 8 – Stockholders’ (Deficit) Equity‌

Common Stock

On February 2, 2025, the Company entered into a marketing agreement with a vendor in which the Company agreed to issue 60,000 shares of common stock in exchange for marketing services. The fair value of the common stock was established as a prepaid expense and the Company recognized $81,600 of the expense over the two-month term of the contract. The shares were issued on February 2, 2025.

On March 20, 2025, the Company entered into a marketing agreement with a vendor in which the Company agreed to issue 100,000 shares of common stock in exchange for digital marketing services. The fair value of the common stock was established as a prepaid expense and the Company recognized $70,100 of the expense over the three-month term of the contract. On April 11, 2025, the Company issued the 100,000 shares of common stock to the vendor using the market value of $77,000 on that date. The difference between the original expense amount and the value when the shares were issued was reflected in the change in fair value of equity payable in other (income) expense on the condensed consolidated statements of operations.

On May 1, 2025, the Company entered into a marketing agreement with a vendor in which the Company agreed to issue 100,000 shares of common stock in exchange for marketing services. The fair value of the common stock was established as a prepaid expense and the Company recognized $51,800 of the expense over the two-month term of the contract. On May 13, 2025, the Company issued the 100,000 shares of common stock to the vendor using the market value of $51,800 on that date.

On August 1, 2025, the Company entered into a marketing agreement with a vendor in which the Company agreed to issue 160,000 shares of common stock in exchange for marketing services. The fair value of the common stock was established as a prepaid expense and the Company recognized $29,600 of the expense over the two-month term of the contract. On August 1, 2025, the Company issued the 160,000 shares of common stock to the vendor using the market value of $29,600 on that date.

Equity Purchase Agreement

On June 24, 2025, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Williamsburg Venture Holdings, LLC (the “Purchaser”), whereby the Company has the right, but not the obligation, to sell to the Purchaser, and the Purchaser is obligated to purchase, up to an aggregate of $10.0 million of shares (the “ELOC Shares”) of the Company’s common stock. The term of the Purchase Agreement is the earlier of June 24, 2027, or the date on which the Purchaser has purchased ELOC Shares for an aggregate purchase price of $10.0 million. The Company has also agreed to issue to the Purchaser 426,829 shares common stock (“Commitment Shares”), which will be issued on a pro rata basis as the Company draws down ELOC shares, with any remaining shares to be issued upon termination. The fair value of the Commitment Shares on the date of the Purchase Agreement of $265,957 was established as accrued issuable equity and was expensed, along with approximately $74,000 of additional issuance costs.

Stock-Based Compensation

For the three months ended September 30, 2025 the Company recorded stock-based compensation expense of $73,988 (of which, $17,362 was included in research and development and $56,626 was included in general and administrative expense) related to options issued to employees and consultants. For the three months ended September 30, 2024 the Company recorded stock-based compensation expense of $160,665 (of which, $15,447 was included in research and development and $145,218 was included in general and administrative expense) related to options issued to employees and consultants.

For the nine months ended September 30, 2025 the Company recorded stock-based compensation expense of $205,478 (of which, $48,256 was included in research and development and $157,222 was included in general and administrative expense) related to options issued to employees and consultants. For the nine months ended September 30, 2024 the Company recorded stock-based compensation expense of $544,902 (of which, $46,342 was included in research and development and $498,560 was included in general and administrative expense) related to options issued to employees and board members. As of September 30, 2025 there was $317,710 of unrecognized stock-based compensation expense, which the Company expects to recognize over a weighted average period of 1.9 years

Stock Options

On July 11, 2025, the Company granted ten-year stock options to purchase 377,964 shares of common stock to employees and directors of the Company under the 2022 Plan. The stock options have an aggregate grant date value of $201,296, vest annually over three years and have an exercise price of $0.59 per share.

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

The grant date fair value of stock options granted during the three and nine months September 30, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

Schedule of Stock Options Granted

	For the Three Months Ended					For the Nine Months Ended
	September 30,					September 30,
	2025			2024		2025			2024
Fair value of common stock on date of grant	$	0.59			N/A	$	0.59			N/A
Risk free interest rate		4.09	%		N/A		4.09	%		N/A
Expected term (years)		6.00			N/A	$	6.00			N/A
Expected volatility		130	%		N/A		130	%		N/A
Expected dividends		0.00	%		N/A		0.00	%		N/A

A summary of the option activity for the nine months ended September 30, 2025 is presented below:

Schedule of Stock Options Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, January 1, 2025		9,612		$	2,248.58
Granted		377,964			0.59
Exercised		-			-
Expired		(152	)		1,760.50
Outstanding, September 30, 2025		387,424		$	55.67		9.7	$	-

Exercisable, September 30, 2025		8,112		$	2,598.23		5.3	$	-

The following table presents information related to stock options as of September 30, 2025:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	0.59		377,964		0-		-
$	152.50		4,157		7.6		2,916
$	738.50		286		7.3		191
$	791.00		38		7.4		26
$	1,760.50		1,127		1.4		1,127
$	3,965.50		37		6.7		37
$	4,053.00		2,095		3.5		2,095
$	5,726.00		1,720		5.7		1,720
			387,424		5.3		8,112

Stock Warrants

On March 7, 2025, the Company closed on a private placement (the “Private Placement”) with an institutional investor, pursuant to which the Company sold pre-funded warrants (the “March 2025 Pre-Funded Warrants”) to purchase 2,105,265 shares of common stock and Series A-3 common warrants (the “March 2025 Common Warrants”) to purchase 2,105,265 shares of common stock at a combined purchase price of $0.9499 which resulted in gross proceeds of approximately $2.0 million. In addition, the Company and the investor executed an amendment to certain November 5, 2024 common share purchase warrants to reduce the exercise price of certain outstanding warrants to purchase 957,200 shares of common stock from $2.06 per share to $1.00 per share. The $53,890 incremental fair value of the modified warrants as compared to the original warrants was recognized as an additional issuance cost of the Private Placement. The March 2025 Pre-Funded Warrants are exercisable immediately, may be exercised at any time until all March 2025 Pre-Funded Warrants are exercised in full, and have an exercise price of $0.0001 per share. As of September 30, 2025, all March 2025 Pre-Funded Warrants were exercised. The March 2025 Common Warrants became exercisable upon Stockholder Approval on June 11, 2025 for a term of five years and have an exercise price of $1.00 per share. Total cash issuance costs were $282,849 including $199,863 of placement fees, $56,844 of legal fees, and $26,142 of other costs.

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

Warrant Inducement Offer

On July 8, 2025, the Company entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with a holder (the “Holder”) of (i) outstanding Series A-2 common stock purchase warrants, as amended (the “Series A-2 Warrants”), exercisable for up to an aggregate of 957,200 shares of the Company’s common stock, and (ii) Series A-3 common stock purchase warrants (the “Series A-3 Warrants” and together with the Series A-2 Warrants, the “Existing Warrants”) exercisable for up to an aggregate of 2,105,265 shares of common stock, which warrants were originally issued by the Company on November 5, 2024 and March 5, 2024, respectively. The Existing Warrants had an exercise price of $1.00 per share.

The Holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $0.67 per share in consideration of the Company’s agreement to issue the Holder new warrants to purchase up to a number of shares of common stock equal to 200% of the number of shares of common stock issued pursuant to the Holder’s exercise of Existing Warrants, comprised of new Series A-4 warrants to purchase up to 6,124,930 shares of common stock (the “Inducement Warrants”) at an exercise price of $0.67 per share with an exercise term of 5 years from the initial exercise date. The Company received $2,051,852 in cash proceeds and incurred $175,221 in transaction costs consisting of $133,370 cash fee paid to its financial advisor and $41,851 in other fees. As a result of the reduction in exercise price of the Existing Warrants, the Company recognized a non-cash warrant modification charge of $1,762,756. Because the modification represented a short-term inducement, modification accounting was only performed on the warrants that were actually exercised under the program. The Company recognized the $1,762,756 modification-date incremental value of the modified Existing Warrants and Inducement Warrants issued as compared to the original Existing Warrants, as an issuance cost of the warrant exercise, which was classified as equity with no impact on the condensed consolidated statements of operations. The initial exercise date of the Inducement Warrants is the date that the Company’s stockholders approve the issuance of shares of common stock underlying the warrants (the “Inducement Warrants Shares”) pursuant to the applicable rules and regulations of The Nasdaq Stock Market LLC (“Nasdaq”). On October 6, 2025, Nasdaq filed with the SEC a Form 25, removing and delisting the Company’s securities from Nasdaq. Based on the foregoing and because applicable rules and regulations of the OTC Markets Group Inc. do not require stockholder approval for the issuance of the Inducement Warrant Shares, the Company noted that stockholder approval is no longer required.

The modification date fair value of warrants modified during the three and nine months ended September 30, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024
Fair value of common stock on date of modification	$	0.64		$	3.46			$0.64 - $0.98		$	3.46
Risk free interest rate		3.92	%		3.62% - 4.62	%		3.92% - 4.09	%		3.62% - 4.62	%
Expected term (years)		4.9 years			0.9 - 5.5 years			4.9 - 5.3 years			0.9 - 5.5 years
Expected volatility		125	%		96% - 113	%		125	%		96% - 113	%
Expected dividends		n/a			n/a			n/a			n/a

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

A summary of the warrant activity for the nine months ended September 30, 2025, is presented below:

Schedule of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, January 1, 2025		1,747,093		$	59.59
Issued^[1]		8,230,195			0.75
Repriced - Old ^[2]		(957,200	)		2.06
Repriced - New ^[2]		957,200			1.00
Repriced - Old ^[3]		(957,200	)		1.00
Repriced - New ^[3]		957,200			0.67
Repriced - Old ^[4]		(2,105,265	)		1.00
Repriced - New ^[4]		2,105,265			0.67
Forfeited		(3,050	)		12.50
Exercised^[1]		(3,062,465	)		0.67
Outstanding, September 30, 2025		6,911,773		$	15.34		4.73	$	-

Exercisable, September 30, 2025		6,911,573		$	15.29		4.73	$	-

[1]	Warrants issued and exercised exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.

[2]	Warrants represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.

[3]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 957,200 shares of common stock from $1.00 to $0.67 per share.

[4]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 2,105,265 shares of common stock from $1.00 to $0.67 per share.

The following table presents information related to stock warrants as of September 30, 2025:

Warrants Outstanding				Warrants Exercisable
		Outstanding		Weighted Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Warrants		In Years		Warrants
$	0.67		6,124,930		4.77		6,124,930
$	2.06		679,800		4.69		679,800
$	12.50		4,050		3.20		4,050
$	47.50		20,347		3.45		20,347
$	57.75		19,965		2.77		19,965
$	350.00		27,551		2.57		27,551
$	700.00		13,944		2.20		13,944
$	1,760.50		200		-		-
$	2,415.00		3,651		2.20		3,651
$	4,025.00		17,335		2.20		17,335
			6,911,773		4.73		6,911,573

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Going Concern and Management’s Plans

9 Months Ended

Sep. 30, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern and Management’s Plans

Note 2 - Going Concern and Management’s Plans

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

As of September 30, 2025, the Company had cash of approximately $0.5 million and a working capital deficit of approximately $11.8 million. During the nine months ended September 30, 2025, the Company incurred a net loss of approximately $24.3 million and used cash in operations of approximately $4.7 million. The Company has an accumulated deficit of approximately $136.9 million as of September 30, 2025.

The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.

Consequently, the Company will be required to raise additional funds through equity or debt financing. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2025

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies‌

Since the date the Company’s December 31, 2024 financial statements were issued in its 2024 Annual Report on Form 10-K, there have been no material changes to the Company’s significant accounting policies.

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

Use of Estimates

Net Loss Per Common Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	As of September 30,
	2025		2024
Warrants ^[1]		6,911,773		928,593
Options		387,424		9,639
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		7,301,336		940,371

[1]

Segment Reporting

Vendor Concentration

Recently Issued Accounting Pronouncements

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Flows From Operating Activities:
Net loss	$ (24,273,806)	$ (7,991,736)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of in-process research and development	18,647,903
Stock-based compensation	205,478	544,902
Issuance of common stock pursuant to vendor agreements	240,000	79,200
Depreciation of fixed assets		6,933
Non-cash rent expense		7,839
Deferred tax (benefit) provision	(851,659)	9,707
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(113,319)	(52,035)
Accounts payable	371,006	676,178
Vendor deposits	7,048	(80,000)
Operating lease liability		(8,656)
Accrued expenses and other current liabilities	1,066,657	502,839
Net Cash Used In Operating Activities	(4,700,692)	(6,304,829)
Cash Flows From Financing Activities:
Exercise of warrants		2,672,500
Private placement of warrants	1,999,791
Warrant inducement offer - exercise proceeds	2,051,852	827,978
Exercise of pre-funded warrants	210
Deferred offering costs	12,511	(30,260)
Registration and issuance costs associated with warrant issuance	(366,618)	(180,142)
Net Cash Provided By Financing Activities	3,697,746	3,290,076
Net Decrease in Cash	(1,002,946)	(3,014,753)
Cash - Beginning of Period	1,530,924	3,137,674
Cash - End of Period	527,978	122,921
Supplemental Disclosures of Cash Flow Information:
Interest
Income taxes
Non-cash investing and financing activities:
Warrant modification - incremental value	1,816,646	246,912
Accounts payable and accrued expenses for offering costs	$ 98,921	$ 176,870

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2025	Dec. 31, 2024
Current Assets:
Cash	$ 527,978	$ 1,530,924
Prepaid expenses and other current assets	298,192	184,873
Vendor deposits	169,363
Total Current Assets	995,533	1,715,797
In-process research and development		18,647,903
Vendor deposits		178,476
Deferred offering costs	44,727	57,238
Total Assets	1,040,260	20,599,414
Current Liabilities:
Accounts payable	9,805,129	9,337,267
Accrued expenses and other current liabilities	2,960,698	1,894,041
Total Current Liabilities	12,765,827	11,231,308
Deferred tax liability		851,659
Total Liabilities	12,765,827	12,082,967
Commitments and contingencies (Note 7)
Stockholders’ (Deficit) Equity:
Common stock	809	251
Additional paid-in-capital	125,187,156	121,155,922
Accumulated deficit	(136,906,365)	(112,632,559)
Treasury stock, at cost, 7 shares at September 30, 2025 and December 31, 2024	(7,168)	(7,168)
Total Stockholders’ (Deficit) Equity	(11,725,567)	8,516,447
Total Liabilities and Stockholders’ (Deficit) Equity	1,040,260	20,599,414
Series A Preferred Stock [Member]
Stockholders’ (Deficit) Equity:
Preferred stock
Series B Preferred Stock [Member]
Stockholders’ (Deficit) Equity:
Preferred stock	$ 1	$ 1

Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2024
Statement of Stockholders' Equity [Abstract]
Gross proceeds	$ 2,051,852	$ 1,999,791	$ 827,978
Cash issuance costs	175,221	282,849	427,054
Non cash warrant modification charges	$ 1,762,756	$ 53,890	$ 246,912

Schedule of Issuance Date Fair Value of Stock Warrants (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free interest rate	4.09%		4.09%
Expected term (years)	6 years		6 years
Expected volatility	130.00%		130.00%
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of common stock on date of grant	$ 0.64	$ 3.46		$ 3.46
Risk free interest rate	3.92%
Expected term (years)	4 years 10 months 24 days
Expected volatility	125.00%		125.00%
Warrant [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of common stock on date of grant			$ 0.64
Risk free interest rate		3.62%	3.92%	3.62%
Expected term (years)		10 months 24 days	4 years 10 months 24 days	10 months 24 days
Expected volatility		96.00%		96.00%
Warrant [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of common stock on date of grant			$ 0.98
Risk free interest rate		4.62%	4.09%	4.62%
Expected term (years)		5 years 6 months	5 years 3 months 18 days	5 years 6 months
Expected volatility		113.00%		113.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Commitments and Contingencies (Details Narrative)							3 Months Ended		9 Months Ended
Commitments and Contingencies (Details Narrative)	Jul. 24, 2025 USD ($)	Jan. 09, 2025 USD ($)	Jul. 01, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jan. 15, 2024 USD ($)	Jan. 18, 2019 USD ($) ft²	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)
Loss Contingencies [Line Items]
Invoices from a vendor			$ 162,800	$ 992,176
Accrued interest							$ 2,960,698		$ 2,960,698		$ 1,894,041
Defined benefit	$ 37,421
Unaccrued interest							1,067,305		1,067,305
Number of operating lease square feet \| ft²						3,500
Lease cost						$ 89,000
Operating lease rent expense						$ 497,000	42,443	$ 42,696	131,807	$ 127,439
Lease Commitment [Member]
Loss Contingencies [Line Items]
Operating lease rent expense		$ 120,819			$ 112,064
Accrued Expenses and Other Current Liabilities [Member]
Loss Contingencies [Line Items]
Accrued interest							$ 649,327		$ 649,327		$ 268,972

Business Organization, Nature of Operations and Basis of Presentation

9 Months Ended

Sep. 30, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Organization, Nature of Operations and Basis of Presentation

Note 1 – Business Organization, Nature of Operations and Basis of Presentation

Organization and Operations

ZyVersa Therapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of September 30, 2025 and for the three and nine months ended September 30, 2025 and 2024. The results of operations for the nine months ended September 30, 2025 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025.

On April 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants were proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2024 Reverse Split.

Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the 2024 Reverse Split and adjustment of the conversion price or exercise price of each outstanding equity award, convertible security and warrant as if the transaction had occurred as of the beginning of the earliest period presented.

Schedule of Information Related to Stock Options (Details)	9 Months Ended
	Sep. 30, 2025 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Number of options	387,424
Options exercisable, weighted average remaining life in years	5 years 3 months 18 days
Options exercisable, Number of options	8,112
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 0.59
Options outstanding, Number of options	377,964
Options exercisable, weighted average remaining life in years	0 years
Options exercisable, Number of options
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 152.50
Options outstanding, Number of options	4,157
Options exercisable, weighted average remaining life in years	7 years 7 months 6 days
Options exercisable, Number of options	2,916
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 738.50
Options outstanding, Number of options	286
Options exercisable, weighted average remaining life in years	7 years 3 months 18 days
Options exercisable, Number of options	191
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 791.00
Options outstanding, Number of options	38
Options exercisable, weighted average remaining life in years	7 years 4 months 24 days
Options exercisable, Number of options	26
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 1,760.50
Options outstanding, Number of options	1,127
Options exercisable, weighted average remaining life in years	1 year 4 months 24 days
Options exercisable, Number of options	1,127
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 3,965.50
Options outstanding, Number of options	37
Options exercisable, weighted average remaining life in years	6 years 8 months 12 days
Options exercisable, Number of options	37
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 4,053.00
Options outstanding, Number of options	2,095
Options exercisable, weighted average remaining life in years	3 years 6 months
Options exercisable, Number of options	2,095
Exercise Price Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 5,726.00
Options outstanding, Number of options	1,720
Options exercisable, weighted average remaining life in years	5 years 8 months 12 days
Options exercisable, Number of options	1,720

Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Unaudited) - USD ($)

Preferred Stock [Member]

Series A Preferred Stock [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Common Stock [Member]

Treasury Common and Preferred Stock [Member]

AOCI Attributable to Parent [Member]

Retained Earnings [Member]

Total

Balance at Dec. 31, 2023

$ 1

$ 40

$ (7,168)

$ 114,300,849

$ (103,219,124)

$ 11,074,598

Balance, shares at Dec. 31, 2023

5,062

405,212

(7)

Issuance of common stock pursuant to vendor agreements

$ 1

79,199

79,200

Issuance of common stock pursuant to vendor agreements, shares

9,000

Stock-based compensation

223,573

Net loss

(2,826,737)

Exercise of pre-funded warrants

$ 13

(13)

Exercise of pre-funded warrants, shares

131,481

Exercise of warrants

$ 21

2,672,479

2,672,500

Exercise of warrants, shares

213,800

Round up share adjustment due to reverse split

$ 8

(8)

Round up share adjustment due to reverse split, shares

75,410

Balance at Mar. 31, 2024

$ 1

$ 83

$ (7,168)

117,276,079

(106,045,861)

11,223,134

Balance, shares at Mar. 31, 2024

5,062

834,903

(7)

Balance at Dec. 31, 2023

$ 1

$ 40

$ (7,168)

114,300,849

(103,219,124)

11,074,598

Balance, shares at Dec. 31, 2023

5,062

405,212

(7)

Net loss

(7,991,736)

Balance at Sep. 30, 2024

$ 1

$ 107

$ (7,168)

118,245,220

(111,210,860)

7,027,300

Balance, shares at Sep. 30, 2024

5,062

1,074,203

(7)

Balance at Mar. 31, 2024

$ 1

$ 83

$ (7,168)

117,276,079

(106,045,861)

11,223,134

Balance, shares at Mar. 31, 2024

5,062

834,903

(7)

Stock-based compensation

160,664

Net loss

(2,763,743)

Balance at Jun. 30, 2024

$ 1

$ 83

$ (7,168)

117,436,743

(108,809,604)

8,620,055

Balance, shares at Jun. 30, 2024

5,062

834,903

(7)

Warrant modification

246,912

Stock-based compensation

160,665

Net loss

(2,401,256)

Warrant inducement offer - exercise proceeds

^[1]

$ 24

400,900

400,924

Warrant inducement offer - exercise proceeds, shares

^[1]

239,300

Balance at Sep. 30, 2024

$ 1

$ 107

$ (7,168)

118,245,220

(111,210,860)

7,027,300

Balance, shares at Sep. 30, 2024

5,062

1,074,203

(7)

Balance at Dec. 31, 2024

$ 1

$ 251

$ (7,168)

121,155,922

(112,632,559)

8,516,447

Balance, shares at Dec. 31, 2024

5,062

2,508,198

(7)

Issuance of common stock pursuant to vendor agreements

$ 6

81,594

81,600

Issuance of common stock pursuant to vendor agreements, shares

60,000

Private placement of warrants additional offering costs

^[2]

1,663,052

Warrant modification

53,890

Stock-based compensation

72,291

Net loss

(2,256,930)

Balance at Mar. 31, 2025

$ 1

$ 257

$ (7,168)

123,026,749

(114,889,489)

8,130,350

Balance, shares at Mar. 31, 2025

5,062

2,568,198

(7)

Balance at Dec. 31, 2024

$ 1

$ 251

$ (7,168)

121,155,922

(112,632,559)

8,516,447

Balance, shares at Dec. 31, 2024

5,062

2,508,198

(7)

Net loss

$ (24,273,806)

Exercise of pre-funded warrants, shares

Balance at Sep. 30, 2025

$ 1

$ 809

$ (7,168)

125,187,156

(136,906,365)

$ (11,725,567)

Balance, shares at Sep. 30, 2025

5,062

8,095,928

(7)

Balance at Mar. 31, 2025

$ 1

$ 257

$ (7,168)

123,026,749

(114,889,489)

8,130,350

Balance, shares at Mar. 31, 2025

5,062

2,568,198

(7)

Issuance of common stock pursuant to vendor agreements

$ 20

128,780

128,800

Issuance of common stock pursuant to vendor agreements, shares

200,000

Private placement of warrants additional offering costs

(7,468)

Stock-based compensation

59,199

Net loss

(2,211,317)

Exercise of pre-funded warrants

$ 210

210

Exercise of pre-funded warrants, shares

2,105,265

Balance at Jun. 30, 2025

$ 1

$ 487

$ (7,168)

123,207,260

(117,100,806)

6,099,774

Balance, shares at Jun. 30, 2025

5,062

4,873,463

(7)

Issuance of common stock pursuant to vendor agreements

$ 16

29,584

29,600

Issuance of common stock pursuant to vendor agreements, shares

160,000

Warrant modification

1,762,756

Stock-based compensation

73,988

Net loss

(19,805,559)

Warrant inducement offer - exercise proceeds

^[3]

$ 306

113,568

113,874

Warrant inducement offer - exercise proceeds, shares

^[3]

3,062,465

Balance at Sep. 30, 2025

$ 1

$ 809

$ (7,168)

$ 125,187,156

$ (136,906,365)

$ (11,725,567)

Balance, shares at Sep. 30, 2025

5,062

8,095,928

(7)

[1]	Includes gross proceeds of $827,978 less issuance costs of $427,054
[2]	Includes gross proceeds of $1,999,791 less cash issuance costs of $282,849 and a non-cash warrant modification charge of $53,890
[3]	Includes gross proceeds of $2,051,852 less cash issuance costs of $175,221 and a non-cash warrant modification charge of $1,762,756

Going Concern and Management’s Plans (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 527,978						$ 527,978		$ 1,530,924
Working capital deficit	11,800,000						11,800,000
Net loss	19,805,559	$ 2,211,317	$ 2,256,930	$ 2,401,256	$ 2,763,743	$ 2,826,737	24,273,806	$ 7,991,736
Net cash used In operations							(4,700,692)	$ (6,304,829)
Accumulated deficit	$ 136,906,365						$ 136,906,365		$ 112,632,559

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 45
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477796/946-210-45-21

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-SubTopic 210
-Topic 946
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477796/946-210-45-20

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($)	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (19,805,559)	$ (2,211,317)	$ (2,256,930)	$ (2,401,256)	$ (2,763,743)	$ (2,826,737)	$ (24,273,806)	$ (7,991,736)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Stockholders’ (Deficit) Equity (Tables)

9 Months Ended

Sep. 30, 2025

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Stock Options Granted

The grant date fair value of stock options granted during the three and nine months September 30, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

Schedule of Stock Options Granted

	For the Three Months Ended					For the Nine Months Ended
	September 30,					September 30,
	2025			2024		2025			2024
Fair value of common stock on date of grant	$	0.59			N/A	$	0.59			N/A
Risk free interest rate		4.09	%		N/A		4.09	%		N/A
Expected term (years)		6.00			N/A	$	6.00			N/A
Expected volatility		130	%		N/A		130	%		N/A
Expected dividends		0.00	%		N/A		0.00	%		N/A

Schedule of Stock Options Activity

A summary of the option activity for the nine months ended September 30, 2025 is presented below:

Schedule of Stock Options Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, January 1, 2025		9,612		$	2,248.58
Granted		377,964			0.59
Exercised		-			-
Expired		(152	)		1,760.50
Outstanding, September 30, 2025		387,424		$	55.67		9.7	$	-

Exercisable, September 30, 2025		8,112		$	2,598.23		5.3	$	-

Schedule of Information Related to Stock Options

The following table presents information related to stock options as of September 30, 2025:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	0.59		377,964		0-		-
$	152.50		4,157		7.6		2,916
$	738.50		286		7.3		191
$	791.00		38		7.4		26
$	1,760.50		1,127		1.4		1,127
$	3,965.50		37		6.7		37
$	4,053.00		2,095		3.5		2,095
$	5,726.00		1,720		5.7		1,720
			387,424		5.3		8,112

Schedule of Warrant Activity

A summary of the warrant activity for the nine months ended September 30, 2025, is presented below:

Schedule of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, January 1, 2025		1,747,093		$	59.59
Issued^[1]		8,230,195			0.75
Repriced - Old ^[2]		(957,200	)		2.06
Repriced - New ^[2]		957,200			1.00
Repriced - Old ^[3]		(957,200	)		1.00
Repriced - New ^[3]		957,200			0.67
Repriced - Old ^[4]		(2,105,265	)		1.00
Repriced - New ^[4]		2,105,265			0.67
Forfeited		(3,050	)		12.50
Exercised^[1]		(3,062,465	)		0.67
Outstanding, September 30, 2025		6,911,773		$	15.34		4.73	$	-

Exercisable, September 30, 2025		6,911,573		$	15.29		4.73	$	-

[1]	Warrants issued and exercised exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.

[2]	Warrants represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.

[3]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 957,200 shares of common stock from $1.00 to $0.67 per share.

[4]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 2,105,265 shares of common stock from $1.00 to $0.67 per share.

Schedule of Information Related to Stock Warrants

The following table presents information related to stock warrants as of September 30, 2025:

Warrants Outstanding				Warrants Exercisable
		Outstanding		Weighted Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Warrants		In Years		Warrants
$	0.67		6,124,930		4.77		6,124,930
$	2.06		679,800		4.69		679,800
$	12.50		4,050		3.20		4,050
$	47.50		20,347		3.45		20,347
$	57.75		19,965		2.77		19,965
$	350.00		27,551		2.57		27,551
$	700.00		13,944		2.20		13,944
$	1,760.50		200		-		-
$	2,415.00		3,651		2.20		3,651
$	4,025.00		17,335		2.20		17,335
			6,911,773		4.73		6,911,573

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Issuance Date Fair Value of Stock Warrants

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024
Fair value of common stock on date of modification	$	0.64		$	3.46			$0.64 - $0.98		$	3.46
Risk free interest rate		3.92	%		3.62% - 4.62	%		3.92% - 4.09	%		3.62% - 4.62	%
Expected term (years)		4.9 years			0.9 - 5.5 years			4.9 - 5.3 years			0.9 - 5.5 years
Expected volatility		125	%		96% - 113	%		125	%		96% - 113	%
Expected dividends		n/a			n/a			n/a			n/a

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

+ Details

Accrued Expenses and Other Current Liabilities

9 Months Ended

Sep. 30, 2025

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Note 5 – Accrued Expenses and Other Current Liabilities‌

Accrued expenses and other current liabilities consisted of the following as of September 30, 2025 and December 31, 2024:

	September 30,		December 31,
	2025		2024

Payroll accrual	$	1,101,584	$	1,039,338
Bonus accrual		1,107,813		536,500
Other accrued expenses		681,296		310,942
Accrued issuable equity		62,744		-
Registration delay liability		7,261		7,261
Total accrued expenses and other current liabilities	$	2,960,698	$	1,894,041

Commitments and Contingencies

9 Months Ended

Sep. 30, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 7 – Commitments and Contingencies

Litigations, Claims and Assessments

The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable.

Disputed Vendor Invoices

On June 30, 2024 and July 1, 2024, the Company received two invoices from a vendor in the amounts of $992,176 and $162,800, respectively. The June 30, 2024 invoice represents retroactive interest on invoices going back to September 30, 2022. The July 1, 2024 invoice included miscellaneous unsupported charges performed over the past several years. On August 1, 2024, ZyVersa management sent the vendor a letter disputing the interest and unsupported charges and has requested the vendor to rescind each of them. Although the Company has requested the vendor to rescind the retroactive interest on invoices, the Company believes that, in accordance with the agreement, the vendor can legally charge the Company interest from the point they were notified of the vendor’s intent to charge interest. As such, the Company included the calculated interest from July 1, 2024 to September 30, 2025 and July 1, 2024 to December 31, 2024 of $649,327 and $268,972, respectively, within accrued expenses and other current liabilities on the condensed consolidated balance sheets at September 30, 2025 and December 31, 2024. On July 24, 2025, the Company received a $37,421 credit memo from the vendor for overcharged interest. The Company has accounted for the unaccrued interest and unsupported charges of $1,067,305 as a loss contingency and because payment is not deemed probable, it has not been recorded as a liability in the condensed consolidated balance sheet as of September 30, 2025.

Operating Leases

On January 18, 2019, the Company entered into a lease agreement for approximately 3,500 square feet of office space in Weston, Florida for a term of five years. Under the lease agreement, the annual base rent, which excludes the Company’s share of taxes and operating costs, was approximately $89,000 for the first year and has increased approximately 3% every year thereafter for a total base rent lease commitment of approximately $497,000. On January 15, 2024, the Company extended the lease for an additional year for a total base rent lease commitment of $112,064. On January 9, 2025, the Company extended the lease for an additional year for a total base rent lease commitment of approximately $120,819. The Company used the short-term lease practical expedient which permits the Company to not capitalize leases with a term equal to or less than 12 months.

The Company recognized rent expense in connection with its operating lease for the three months ended September 30, 2025 and 2024 of $42,443 and $42,696, respectively.

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

The Company recognized rent expense in connection with its operating lease for the nine months ended September 30, 2025 and 2024 of $131,807 and $127,439, respectively.

Business Organization, Nature of Operations and Basis of Presentation (Details Narrative)	Apr. 25, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock.

Schedule of Stock Options Activity (Details)	9 Months Ended
Schedule of Stock Options Activity (Details)	Sep. 30, 2025 USD ($) $ / shares shares
Equity [Abstract]
Number of options, outstanding beginning balance \| shares	9,612
Weighted average exercise price, beginning balance \| $ / shares	$ 2,248.58
Number of options, granted \| shares	377,964
Weighted average exercise price, granted \| $ / shares	$ 0.59
Number of options, exercised \| shares
Weighted average exercise price, exercised \| $ / shares
Number of options, forfeited \| shares	(152)
Weighted average exercise price, forfeited \| $ / shares	$ 1,760.50
Number of options, outstanding ending balance \| shares	387,424
Weighted average exercise price, ending balance \| $ / shares	$ 55.67
Weighted average remaining life in years, outstanding	9 years 8 months 12 days
Aggregate intrinsic value, ending balance \| $
Number of options, exercisable ending balance \| shares	8,112
Weighted average exercise price, Exercisable \| $ / shares	$ 2,598.23
Weighted average remaining life in years, exercisable	5 years 3 months 18 days
Aggregate intrinsic value, exercisable \| $